Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  Issue: February 2021  |  February 16, 2021

Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward.

Background

Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler noted in 1892 that patients with scleroderma were “apt to succumb to pulmonary complaints or to nephritis.”1 Awareness of the condition increased in 1952 with a case report of three patients appearing in The Lancet.2 More case reports and limited reviews of the topic were published, but the disease’s causes, incidence and disease course were not well characterized. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Once such case report from 1960 noted the aggressive, fulminant presentation of scleroderma renal crisis: “The hypertension is rapidly followed by retinopathy, cardiac failure, convulsions, profound oliguria and uraemia. The progression of the disease from the appearance of hypertension to death is usually so rapid that there is little time for clinical evidence of renal disease to become fully apparent.”1 The disease was almost always fatal, until the first reported successful nephrectomy followed by renal transplant in 1970.3

In 1974, a seminal paper on scleroderma and renal disease appeared, a clinicopathological review of 210 patients with scleroderma seen over the previous 20 years. The detailed 46-page report included thorough case studies, clinical evaluations, renal blood flow measures, such lab analyses as renin, treatment outcomes and information about renal histopathology. The writers also hypothesized about the pathogenic role of renin release in scleroderma renal crisis.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The research team, headed by E. Carwile LeRoy, MD, found evidence of some type of renal involvement in 45% of scleroderma patients, lumping together such markers as proteinuria, hypertension and azotemia. Some of these patients had only low-level, asymptomatic renal disease. Critically, the team reported that the syndrome of malignant hypertension (scleroderma renal crisis), characterized by rapidly progressive renal damage, occurred in 7% of their patients and was fatal in 12 out of these 15 cases. For all patients, scleroderma renal crisis was the leading cause of death.4

Dr. Whitman

Dr. Whitman

Hendricks H. Whitman III, MD, FACP, an assistant professor of medicine at Weill Cornell Medical College, New York City, notes, “In those days, if scleroderma patients became hypertensive and their kidneys began to be damaged, that’s what actually killed them. Scleroderma patients had about a 50% mortality in 10 years. And almost all of them died from hypertension or renal failure.”

A few scattered reports appeared of successful aggressive medical management of scleroderma renal crisis with such agents as minoxidil, but the prognosis was grim.5,6 Virginia D. Steen, MD, a professor and chief of the Division of Rheumatology of the Department of Medicine at Georgetown University in Washington, D.C., recounts, “Even when I was a fellow, we kept trying all these kinds of medications, and nothing did anything. I remember vividly as a student, being in a conference where they decided to do a bilateral nephrectomy on a young woman as the only way to save her life.” 

Dr. Whitman recalls how patients with scleroderma and baseline hypertension were managed then. “We didn’t know any better in those days, so we’d give them a diuretic, which would actually make things worse rather than better, or we’d give them a beta blocker, and that would be really bad for their Raynaud’s phenomenon.” Some rheumatologists observed that scleroderma renal crisis was sometimes triggered by diuretic therapy initiated to control a baseline high blood pressure.6

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

Related Articles
    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Can Technology Help Solve Scleroderma Renal Crisis?

    December 1, 2010

    A case study in using the Internet to facilitate rare disease research

    Case Report: A Patient Develops Scleroderma Renal Crisis

    October 18, 2019

    Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences